Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14454097 | 0.79 | POLB (0.43) | ALDH1A1KMT2AHTTMAPTKDM4E | |
| SCHEMBL530858 | 0.77 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1KMT2ANR3C1 | |
| SCHEMBL3014819 | 0.76 | PTGS2 (0.51) | ALDH1A1KMT2APTGS1PTGS2MAPT | |
| SCHEMBL311565 | 0.75 | PARP1 (0.46) | ALDH1A1KMT2AL3MBTL1MAPTKDM4E | |
| SCHEMBL1290987 | 0.75 | KEAP1 (0.67) | KEAP1NFE2L2ALDH1A1KMT2ANR3C1 | |
| SCHEMBL11277079 | 0.75 | POLB (0.52) | KEAP1ALDH1A1L3MBTL1HPGDHSD17B10 | |
| SCHEMBL5264765 | 0.75 | ALDH1A1 (0.41) | ALDH1A1KMT2AHTTMAPTKDM4E | |
| SCHEMBL15108064 | 0.74 | KEAP1 (1.00) | KEAP1NFE2L2ALDH1A1KMT2ANR3C1 | |
| SCHEMBL1476351 | 0.74 | KEAP1 (0.70) | KEAP1NFE2L2ALDH1A1KMT2AGLO1 | |
| SCHEMBL1127360 | 0.74 | KMT2A (0.65) | ALDH1A1KMT2AHTTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | KEAP1 1536/4885NFE2L2 282/4885ALDH1A1 2230/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1576/4885NFE2L2 300/4885ALDH1A1 2174/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KEAP1 1536/4885NFE2L2 282/4885ALDH1A1 2230/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1576/4885NFE2L2 300/4885ALDH1A1 2174/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KEAP1 1576/4885NFE2L2 281/4885ALDH1A1 2238/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KEAP1 1530/4885NFE2L2 295/4885ALDH1A1 2168/4885 |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KEAP1 1536/4885NFE2L2 282/4885ALDH1A1 2230/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KEAP1 1536/4885NFE2L2 282/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.